Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588393 · ClinicalTrials.gov registry record · Phase 2
FolateScan in Autoimmune Disease
A Phase 2 study of Multiple Sclerosis and Rheumatoid Arthritis, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00588393 is a Phase 2 study of Multiple Sclerosis and Rheumatoid Arthritis that has completed, run by Mayo Clinic. The registered enrollment target is 75 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00588393, a Phase 2 study of Multiple Sclerosis and Rheumatoid Arthritis, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will gather information on the safety of FolateScan and the ability of FolateScan to detect inflammation in the joints and other organs in people with arthritis (rheumatoid arthritis and osteoarthritis), systemic lupus erythematosus, multiple sclerosis, interstitial pneumonitis, Crohn's disease as well as in healthy persons without these conditions.
Conditions Studied
Interventions
- DRUG FolateScan (Technetium Tc 99mEC20)
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00588393
The ClinicalTrials.gov registry entry for NCT00588393 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (87% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which FolateScan (Technetium Tc 99mEC20) is the first listed.
NCT00588393 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT00588393 about?
NCT00588393 is a clinical study titled "FolateScan in Autoimmune Disease". This study will gather information on the safety of FolateScan and the ability of FolateScan to detect inflammation in the joints and other organs in people with arthritis (rheumatoid arthritis and osteoarthritis), systemic lupus erythematosus, multiple sclerosis, interstitial pneumonitis, Crohn's d...
What is the current status of trial NCT00588393?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2006-09. Estimated completion is 2007-12.
What conditions does trial NCT00588393 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Rheumatoid Arthritis, Osteoarthritis, Crohn's Disease, Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT00588393?
The interventions under investigation include: FolateScan (Technetium Tc 99mEC20) (DRUG).
Who is sponsoring clinical trial NCT00588393?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00588393 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.